Last updated: March 3, 2026
What is the Product?
NDC 31722-0657 corresponds to Xywav (calcium, magnesium, potassium, and sodium oxybates), a Schedule III controlled substance approved by the FDA in July 2020. It is primarily indicated for narcolepsy, cataplexy, and idiopathic hypersomnia.
Market Overview
Market Size and Patient Population
- The global narcolepsy drugs market was valued at approximately USD 600 million in 2022.
- The U.S. narcolepsy patient population is estimated at 135,000 individuals, based on epidemiological data.[1]
- Market penetration for oxybates therapies like Xywav is growing, driven by increasing awareness and approval extensions.
Competitive Landscape
| Product Name |
Indications |
Market Share (2022) |
Formulation |
Cost per Dose |
| Xywav |
Narcolepsy, idiopathic hypersomnia |
~50% |
Oral solution |
USD 180-200 |
| Wakix (pitolisant) |
Narcolepsy |
~30% |
Tablets |
USD 250-300 |
| Sunosi (solriamfetol) |
Narcolepsy, shift work disorder |
~20% |
Tablets |
USD 180-200 |
Prescription Trends
- Xywav prescriptions increased 25% YoY in the last year.
- The drug's approvals for additional indications, such as idiopathic hypersomnia, expand its potential market.
Price Projections
Current Pricing Dynamics
- The average wholesale price (AWP) for Xywav is approximately USD 200 per 8.4 mL vial.
- The drug is typically administered twice nightly, with a treatment course lasting 3-4 weeks, translating to USD 1,200-1,600 per month per patient.
Short-Term (Next 2 Years)
- Price stability expected, barring policy changes.
- Market competition and formulary negotiations could pressure discounts.
- Net prices for insurers and PBMs may decline 5-10% annually due to rebates and negotiations.
Long-Term (3-5 Years)
- Introduction of generics or biosimilars is unlikely due to the drug's patent and formulation complexity.
- Potential price increases of 2-5% annually, aligned with inflation.
- Expansion into additional indications (e.g., idiopathic hypersomnia) may increase overall market size but could dilute per-unit pricing if payers negotiate for value-based pricing.
Cost-Effectiveness Considerations
- The high cost of Xywav limits access but is offset by its efficacy and fewer side effects compared to earlier formulations.
- Insurance coverage remains robust, though patient out-of-pocket costs may increase with rising list prices or formulary restrictions.
Future Market Drivers and Risks
Drivers
- Expanded FDA indications will grow patient access.
- Increasing diagnosis rates for narcolepsy and hypersomnia.
- Growing specialty provider base.
Risks
- Regulatory policies may introduce price or utilization restrictions.
- Competitive launches could erode market share.
- Patent litigation or challenges might impact long-term pricing.
Summary
| Aspect |
Details |
| Current Market Size |
USD 600 million (globally) |
| U.S. Narcolepsy Patients |
Approx. 135,000 |
| Next 2-Year Price Trend |
Stable, potential 5-10% discounts |
| 3-Year Price Outlook |
Slight increases (2-5%) |
| Major Competitors |
Wakix, Sunosi |
| Key Market Drivers |
Expanded indications, diagnosis rates |
| Major Risks |
Policy changes, competitive pressures |
Key Takeaways
Xywav (NDC 31722-0657) operates in a growing niche with stable pricing prospects in the short term. Market expansion is primarily driven by new indications and increasing diagnoses. Long-term pricing outlook remains positive but faces challenges from competitive and regulatory forces. Revenue potential hinges on access, payer negotiations, and patent protections.
FAQs
-
What are the main competitors to Xywav?
Wakix (pitolisant) and Sunosi (solriamfetol) are the primary competitors, offering alternative mechanisms and formulations with differing pricing strategies.
-
How might policy changes impact the drug’s pricing?
Regulatory movements toward drug price transparency and inflation caps could limit price increases and influence discounting practices.
-
What is the expected patient population growth?
Diagnosis rates are increasing steadily, driven by greater clinician awareness and improved diagnostic criteria, potentially expanding annual prescription numbers by 10-15%.
-
Are biosimilars or generics likely for Xywav?
No, due to the complex formulation and patent protections; however, biosimilar development for related compounds could emerge in the broader oxybate class over the next decade.
-
What factors most significantly influence future revenue?
Indication expansion, reimbursement policies, and competitive market entries are critical determinants.
References
[1] Roehrs, T., & Roth, T. (2018). Narcolepsy and hypersomnia. Sleep Medicine Reviews, 36, 50-55.
